Donald M. Berwick, M.D. Announces Candidacy for Massachusetts Governor

June 25, 2013
On June 17, Donald M. Berwick, formerly acting administrator of the federal Centers for Medicare & Medicaid Services (CMS), announced officially that he was entering the 2014 race for governor of the Commonwealth of Massachusetts

On June 17, Donald M. Berwick, formerly acting administrator of the federal Centers for Medicare & Medicaid Services (CMS), announced officially that he was entering the 2014 race for governor of the commonwealth of Massachusetts.

As reported by Joshua Miller in the Boston Globe, via Boston.com, Dr. Berwick said in a statement, “As a doctor, an educator, an innovator and someone who has dedicated his professional career to making things work better and to helping people—I am ready to lead.”

Berwick’s recent history revolves around his tenure at CMS, and the circumstances surrounding that tenure. President Barack Obama nominated Berwick in April 2010 to be CMS administrator;vbut some Republican members of the Senate opposed that nomination, based on his having expressed admiration for the National Health Service of the U.K. and for his expressing the view that comparative effectiveness research would be needed in order to optimize the use of scarce resources in healthcare. As a result of sustained opposition on the part of Republicans in Congress, President Obama installed Dr. Berwick as acting CMS administrator in July 2010, allowing him to serve until the summer of 2011 without Senate approval. In January 2011, the President renominated Berwick, but in March of that year, 42 Republican senators asked for his nomination to be withdrawn. Berwick resigned his position at CMS in December 2011, and was succeeded by Marilyn Tavenner, R.N., in that position.

With regard to the upcoming gubernatorial race, the Globe story notes, “Another Democratic physician, Dr. Joseph Avellone, has already announced a bid for the corner office in 2014. U.S. representative Michael E. Capuano and state treasure Steven Grossman, both Democrats, have said they are pondering bids for governor as well,” the story noted.  “On the Republican side,” it said, “Charles D. Baker, the GOP nominee who lost to Governor Deval Patrick in 2010, is considering another run.”

Dr. Berwick, 66, was for years best known as president and CEO of the Cambridge, Mass.-based Institution for Healthcare Improvement, which he co-founded in 1989, and where he served until 2010.

Sponsored Recommendations

Ask the Expert: Is Your Patients' Understanding Putting You at Risk?

Effective health literacy in healthcare is essential for ensuring informed consent, reducing medical malpractice risks, and enhancing patient-provider communication. Unfortunately...

Beyond the Silos: Transforming Coordinated Care Across Healthcare Systems

Coordinated healthcare is vital to delivering a high-quality patient experience, yet it has been difficult to systematize across all healthcare settings. Although it has largely...

The Healthcare Provider's Guide to Accelerating Clinician Onboarding

Improve clinician satisfaction and productivity to enhance patient care

ASK THE EXPERT: ServiceNow’s Erin Smithouser on what C-suite healthcare executives need to know about artificial intelligence

Generative artificial intelligence, also known as GenAI, learns from vast amounts of existing data and large language models to help healthcare organizations improve hospital ...

According to an Oct. 10 press release, a report by the World Health Organization (WHO) finds that vaccines against 24 pathogens could reduce the number of antibiotics needed by 22% or 2.5 billion defined daily doses globally every year, supporting worldwide efforts to address antimicrobial resistance (AMR). While some of these vaccines are already available but underused, others would need to be developed and brought to the market as soon as possible. AMR occurs when bacteria, viruses, fungi, and parasites no longer respond to antimicrobial medicines, making people sicker and increasing the risk of illness, death and the spread of infections that are difficult to treat. AMR is driven largely by the misuse and overuse of antimicrobials, yet, at the same time, many people around the world do not have access to essential antimicrobials. Each year, nearly 5 million deaths are associated with AMR globally. Vaccines are an essential part of the response to reduce AMR as they prevent infections, reduce the use and overuse of antimicrobials, and slow the emergence and spread of drug-resistant pathogens. The new report expands on a WHO study published in BMJ Global Health last year. It estimates that vaccines already in use against pneumococcus pneumonia, Haemophilus influenzae type B (Hib, a bacteria causing pneumonia and meningitis) and typhoid could avert up to 106 000 of the deaths associated with AMR each year. An additional 543 000 deaths associated with AMR could be averted annually when new vaccines for tuberculosis (TB) and Klebsiella pneumoniae, are developed and rolled out globally. While new TB vaccines are in clinical trials, one against Klebsiella pneumoniae is in early stage of development.
dreamstime_xxl_210174616_1